Chicago – GE HealthCare (Nasdaq: GEHC) announced it has entered into a definitive agreement to acquire icometrix, a Belgium-based company specializing in AI-powered brain imaging analysis for neurological disorders including Alzheimer’s disease, multiple sclerosis, and traumatic brain injury.
The acquisition is designed to strengthen GE HealthCare’s precision care strategy by integrating icometrix’s icobrain platform, a comprehensive suite of FDA-cleared solutions for brain MRI analysis. Notably, icobrain aria is the first AI computer-aided detection and diagnosis (CADe/CADx) solution cleared by the U.S. FDA to identify and quantify amyloid-related imaging abnormalities (ARIA) — known side effects of amyloid-targeting Alzheimer’s therapies.
“By integrating icometrix’s AI-powered insights with our advanced imaging technologies, we aim to empower care teams with the clarity and confidence needed to navigate complex neurological conditions,” said Roland Rott, President & CEO, Imaging at GE HealthCare.
With Alzheimer’s prevalence expected to double by 2050, GE HealthCare anticipates surging demand for MRI scans to assess eligibility and monitor risks associated with emerging Alzheimer’s treatments. The integration of icometrix’s solutions with GE’s MRI systems — including AIR™ Recon DL and SONIC DL 3D — is expected to enable seamless workflows, enhance diagnostic accuracy, and expand patient access to advanced neurological monitoring.
Key Highlights of the Transaction
- Strategic Fit: Enhances GE HealthCare’s neurology portfolio by complementing existing MRI, PET, and pharmaceutical diagnostics platforms.
- Clinical Impact: Provides radiologists with longitudinal tracking tools for Alzheimer’s patients receiving anti-amyloid therapies.
- Broader Pipeline: Supports drug developers and clinical trial sponsors with imaging biomarkers, real-world evidence, and AI-based endpoints.
- Closing: Subject to customary regulatory approvals; financial terms were not disclosed.
About GE HealthCare
GE HealthCare is a global leader in medical technology, pharmaceutical diagnostics, and AI-enabled healthcare solutions, serving providers and patients across 160+ countries with more than $19.7 billion in revenue and 53,000 employees worldwide.
About icometrix
Founded in 2011 and headquartered in Leuven, Belgium, icometrix delivers AI-driven brain imaging solutions used across hospitals and research networks worldwide, while collaborating with biopharma partners on clinical trials and market access.
Media Contact:
Katie Scrivano
GE HealthCare Media Relations
katherine.scrivano@gehealthcare.com
By